Na Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Na Chen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Lan Zhu
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
2 shared publications - Bowen Liu
Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
1 shared publication - Congcong Ma
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
1 shared publication - Fang Chen
MGI Tech, Shenzhen, China
1 shared publication Jia Kang
National Clinical Research Center for Women’s Health and Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
1 shared publication- Jia Kang
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 25 July 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Human papillomavirus awareness and prevention practices among patients with Mayer–Rokitansky–Küster–Hauser syndrome after neovagina reconstruction: a cross-sectional study
Background: Patients with Mayer–Rokitansky–Küster–Hauser syndrome (MRKH) who undergo neovagina reconstruction remain at risk of Human papillomavirus infection (HPV), yet evidence regarding their awareness of HPV-related health risks and engagement in preventive behaviours is limited. This study aimed to assess HPV-related awareness, preventive practices and behavioural factors among Chinese patients with MRKH syndrome after neovagina reconstruction, and to describe HPV screening and vaccination uptake in this population. Methods: A cross-sectional questionnaire-based study was conducted at a tertiary referral hospital in Beijing, China. A total of 157 patients with MRKH syndrome who had undergone neovagina reconstruction completed validated questionnaires assessing HPV awareness, preventive practices and behavioural factors. In addition, outpatient clinical records of 1,756 patients with MRKH syndrome attending specialist care between 2012 and 2024 were retrospectively reviewed to obtain information on HPV testing and ThinPrep cytologic test (TCT) results where available. Descriptive statistical analyses were performed to summarise awareness levels, behavioural characteristics and preventive practice uptake. Results: Most participants demonstrated relatively high awareness of HPV-related health risks: 82.8% recognised their susceptibility to HPV infection and 75.8% expressed support for HPV vaccination. However, preventive practices remained limited. Only 11.5% of participants reported having undergone HPV screening, and 18.5% had received HPV vaccination, indicating a substantial gap between awareness and preventive action. Engagement with routine gynaecological follow-up was generally low. Among those who underwent HPV testing, HPV positivity was detected in a small proportion of patients, with observed rates ranging from 7.4% to 11.1%. Conclusions: Despite relatively high awareness of HPV and its prevention, Chinese patients with MRKH syndrome after neovagina reconstruction showed markedly low uptake of HPV vaccination and limited engagement with HPV testing. These findings highlight an unmet need for accessible HPV vaccination, neovaginal HPV risk education, and tailored sexual health education for this rare and underserved population. Further research is warranted to identify barriers to preventive care and to develop effective interventions to improve HPV prevention practices among women with MRKH syndrome.
- 25 July 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessHuman papillomavirus awareness and prevention practices among patients with Mayer–Rokitansky–Küster–Hauser syndrome after neovagina reconstruction: a cross-sectional study
Background: Patients with Mayer–Rokitansky–Küster–Hauser syndrome (MRKH) who undergo neovagina reconstruction remain at risk of Human papillomavirus infection (HPV), yet evidence regarding their awareness of HPV-related health risks and engagement in preventive behaviours is limited. This study aimed to assess HPV-related awareness, preventive practices and behavioural factors among Chinese patients with MRKH syndrome after neovagina reconstruction, and to describe HPV screening and vaccination uptake in this population. Methods: A cross-sectional questionnaire-based study was conducted at a tertiary referral hospital in Beijing, China. A total of 157 patients with MRKH syndrome who had undergone neovagina reconstruction completed validated questionnaires assessing HPV awareness, preventive practices and behavioural factors. In addition, outpatient clinical records of 1,756 patients with MRKH syndrome attending specialist care between 2012 and 2024 were retrospectively reviewed to obtain information on HPV testing and ThinPrep cytologic test (TCT) results where available. Descriptive statistical analyses were performed to summarise awareness levels, behavioural characteristics and preventive practice uptake. Results: Most participants demonstrated relatively high awareness of HPV-related health risks: 82.8% recognised their susceptibility to HPV infection and 75.8% expressed support for HPV vaccination. However, preventive practices remained limited. Only 11.5% of participants reported having undergone HPV screening, and 18.5% had received HPV vaccination, indicating a substantial gap between awareness and preventive action. Engagement with routine gynaecological follow-up was generally low. Among those who underwent HPV testing, HPV positivity was detected in a small proportion of patients, with observed rates ranging from 7.4% to 11.1%. Conclusions: Despite relatively high awareness of HPV and its prevention, Chinese patients with MRKH syndrome after neovagina reconstruction showed markedly low uptake of HPV vaccination and limited engagement with HPV testing. These findings highlight an unmet need for accessible HPV vaccination, neovaginal HPV risk education, and tailored sexual health education for this rare and underserved population. Further research is warranted to identify barriers to preventive care and to develop effective interventions to improve HPV prevention practices among women with MRKH syndrome.
- 29 July 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (6) , 1334-1336
Association between endometriosis and müllerian anomalies: a retrospective study supporting the retrograde menstruation theory
- 29 July 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (6) , 1334-1336
Association between endometriosis and müllerian anomalies: a retrospective study supporting the retrograde menstruation theory
- Open Access
- 25 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12853
Clinical and Genetic Characteristics of a Cohort with Distal Vaginal Atresia
Distal vaginal atresia is a rare abnormality of female reproductive tract in which the vagina is closed or absent. The distal vagina may be replaced by fibrous tissue and the condition is often not diagnosed until a girl fails to begin having periods at puberty. Although it is a congenital disorder, potential genetic causes of distal vaginal atresia are still unknown. We recruited a cohort of 39 patients with distal vaginal atresia and analyzed their phenotypic and genetic features. In addition to the complaint of distal vaginal atresia, approximately 17.9% (7/39) of the patients had other Müllerian anomalies, and 17.9% (7/39) of the patients had other structural abnormalities, including renal-tract, skeletal and cardiac anomalies. Using genome sequencing, we identified two fragment duplications on 17q12 encompassing HNF1B and LHX1, two dosage-sensitive genes with candidate pathogenic variants, in two unrelated patients. A large fragment of uniparental disomy was detected in another patient, affecting genes involved in cell morphogenesis and connective tissue development. Additionally, we reported two variants on TBX3 and AXL, leading to distal vaginal atresia in mutated mouse model, in our clinical subjects for the first time. Essential biological functions of these detected genes with pathogenic variants included regulating reproductive development and cell fate and patterning during embryogenesis. We displayed the comprehensive clinical and genetic characteristic of a cohort with distal vaginal atresia and they were highly heterogeneous both phenotypically and genetically. The duplication of 17q12 in our cohort could help to expand its phenotypic spectrum and potential contribution to the distal vaginal atresia. Our findings of pathogenic genetic variants and associated phenotypes in our cohort could provide evidence and new insight for further research attempting to reveal genetic causes of distal vaginal atresia.
- 25 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 12853
Open AccessClinical and Genetic Characteristics of a Cohort with Distal Vaginal Atresia
Distal vaginal atresia is a rare abnormality of female reproductive tract in which the vagina is closed or absent. The distal vagina may be replaced by fibrous tissue and the condition is often not diagnosed until a girl fails to begin having periods at puberty. Although it is a congenital disorder, potential genetic causes of distal vaginal atresia are still unknown. We recruited a cohort of 39 patients with distal vaginal atresia and analyzed their phenotypic and genetic features. In addition to the complaint of distal vaginal atresia, approximately 17.9% (7/39) of the patients had other Müllerian anomalies, and 17.9% (7/39) of the patients had other structural abnormalities, including renal-tract, skeletal and cardiac anomalies. Using genome sequencing, we identified two fragment duplications on 17q12 encompassing HNF1B and LHX1, two dosage-sensitive genes with candidate pathogenic variants, in two unrelated patients. A large fragment of uniparental disomy was detected in another patient, affecting genes involved in cell morphogenesis and connective tissue development. Additionally, we reported two variants on TBX3 and AXL, leading to distal vaginal atresia in mutated mouse model, in our clinical subjects for the first time. Essential biological functions of these detected genes with pathogenic variants included regulating reproductive development and cell fate and patterning during embryogenesis. We displayed the comprehensive clinical and genetic characteristic of a cohort with distal vaginal atresia and they were highly heterogeneous both phenotypically and genetically. The duplication of 17q12 in our cohort could help to expand its phenotypic spectrum and potential contribution to the distal vaginal atresia. Our findings of pathogenic genetic variants and associated phenotypes in our cohort could provide evidence and new insight for further research attempting to reveal genetic causes of distal vaginal atresia.
- Open Access
- 14 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1503
Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List
Clinical exome sequencing (CES) has shown great utility in the diagnosis of Mendelian disorders. CES can unravel secondary findings (SFs) unrelated to the primary diagnosis but with potential health implications. The American College of Medical Genetics and Genomics (ACMG) has published a guideline for reporting secondary findings and recently updated an ACMG SF v3.0 list comprising 73 genes. Several studies have been performed to explore the prevalence of SFs. However, the data were limited in the Chinese population. In this study, we evaluated the genetic data of 2987 individuals from the Deciphering Disorders Involving Scoliosis and COmorbidities (DISCO) study group in accordance with the ACMG SF v3.0 list. The detected variants were evaluated using the ACMG classification guidelines, HGMD, and ClinVar database. Totally, 157 (157/2987, 5.3%) individuals had reportable variants within genes associated with cancer, cardiovascular, metabolic, and miscellaneous phenotypes. We identified 63 known pathogenic (KP) variants in 72 individuals (72/2987, 2.4%) and 96 expected pathogenic (EP) variants in 105 individuals (3.5%). Forty-five individuals carried SFs in v3.0 newly added genes, which accounted for 1.5% of our cohort. Our findings could contribute to existing knowledge of secondary findings in different ethnicities and indicate the necessity for clinicians to update the SFs gene list.
- 14 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1503
Open AccessLandscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List
Clinical exome sequencing (CES) has shown great utility in the diagnosis of Mendelian disorders. CES can unravel secondary findings (SFs) unrelated to the primary diagnosis but with potential health implications. The American College of Medical Genetics and Genomics (ACMG) has published a guideline for reporting secondary findings and recently updated an ACMG SF v3.0 list comprising 73 genes. Several studies have been performed to explore the prevalence of SFs. However, the data were limited in the Chinese population. In this study, we evaluated the genetic data of 2987 individuals from the Deciphering Disorders Involving Scoliosis and COmorbidities (DISCO) study group in accordance with the ACMG SF v3.0 list. The detected variants were evaluated using the ACMG classification guidelines, HGMD, and ClinVar database. Totally, 157 (157/2987, 5.3%) individuals had reportable variants within genes associated with cancer, cardiovascular, metabolic, and miscellaneous phenotypes. We identified 63 known pathogenic (KP) variants in 72 individuals (72/2987, 2.4%) and 96 expected pathogenic (EP) variants in 105 individuals (3.5%). Forty-five individuals carried SFs in v3.0 newly added genes, which accounted for 1.5% of our cohort. Our findings could contribute to existing knowledge of secondary findings in different ethnicities and indicate the necessity for clinicians to update the SFs gene list.